Source: Taiwantrade | Updated: 15 July 2011
It is estimated the world’s number of diabetes patients will be doubled by 2030. Aware of this trend, the world’s pharmaceutical giants are actively engaged in a R&D race of diabetes drugs.
Taiwan’s TWi Pharmaceuticals, Inc. is devoted to the development of drug candidate AC-201. The company is collaborating with Cardinal Tien Hospital, China Medical University Hospital, Chung Shan Medical University Hospital for the drug’s phase II clinical trials.
The drug has achieved promising results and is expected to be launched within 3 to 5 years.
Please click on diabetes for related products on Taiwantrade.